8 results about "Gaining weight" patented technology

The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

The present application belongs to the technical field of automatic growth performance determination of pigs, and discloses a kind of sow growth performance determination data correction method, system, equipment and terminal, obtain determination data and are summarized to the determination data table with every pig unit, the determination data table of every pig is matched with the birth information of sow population, obtain the day age, sex, variety information corresponding to every pig;The most suitable intersection between the set formed by calculating each pig during the measurement period (MP) is determined, to determine the most individuals in the whole sow population Correction measurement period;For the missing value of daily weight data and daily feed intake data of each pig in the correction measurement period, fill in the correction, calculate the average daily gain (ADG) and feed conversion ratio (FCR) of each pig in the correction measurement period, calculate the change of body weight of each pig with increasing age in the correction measurement period, and draw the growth curve graph of each pig in the correction measurement period.

The present disclosure relates to methods for treating obesity and / or methods for reducing and maintaining body weight and / or body fat in a patient in need thereof.

The invention concerns methods for treating unwanted body weight loss, and / or medically undesired body weight loss, or eating disorders (such as anorexia nervosa), by administration of a leptin receptor agonist, such as metreleptin. The invention also relates to methods for increasing body weight in a subject in need of the treatment.

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient being treated with a GLP-1 receptor agonist, by administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient are also provided.

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, increasing muscle mass, and / or increasing muscle strength in a subject being treated with a GLP-1 receptor agonist, by administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a subject are also provided.

The invention discloses a novel application of a metabolite of bacillus safensis. The bacillus safensis ZHT-9 is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC NO: M20241011, and the preservation address is the China Center for Type Culture Collection (Wuhan University). The bacillus safensis metabolite is used for feeding SPF (specific pathogen free)-grade mice, and the metabolite has a remarkable blood fat reducing function in animal blood and can also show a unique phenomenon of'unfat after eating more 'in a mouse model.

The present disclosure relates to methods for treating obesity in a patient in need thereof and / or for reducing and maintaining body weight and / or body fat in a patient in need thereof.